SEARCH

SEARCH BY CITATION

References

  • Ang CW, De Klerk MA, Endtz HP, Jacobs BC, Laman JD, Van Der Meche FG & Van Doorn PA (2001) Guillain–Barre syndrome- and Miller Fisher syndrome-associated Campylobacter jejuni lipopolysaccharides induce anti-GM1 and anti-GQ1b antibodies in rabbits. Infect Immunol 69: 24622469.
  • Ang CW, Noordzij PG, De Klerk MA, Endtz HP, Van Doorn PA & Laman JD (2002) Ganglioside mimicry of Campylobacter jejuni lipopolysaccharides determines antiganglioside specificity in rabbits. Infect Immunol 70: 50815085.
  • Aspinall GO, McDonald AG, Raju TS, Pang H, Kurjanczyk LA, Penner JL & Moran AP (1993a) Chemical structure of the core region of Campylobacter jejuni serotype O:2 lipopolysaccharide. Eur J Biochem 213: 10291037.
  • Aspinall GO, McDonald AG, Raju TS, Pang H, Moran AP, Penner JL & Kurjanczyk LA (1993b) Chemical structures of the core regions of Campylobacter jejuni serotypes O:1 O:4 O:23 and O:36 lipopolysaccharides. Eur J Biochem 216: 880.
  • Aspinall GO, Fujimoto S, McDonald AG, Pang H, Kurjanczyk LA & Penner JL (1994a) Lipopolysaccharides from Campylobacter jejuni associated with Guillain–Barre syndrome patients mimic human gangliosides in structure. Infect Immunol 62: 21222125.
  • Aspinall GO, McDonald AG & Pang H (1994b) Lipopolysaccharides of Campylobacter jejuni serotype O:19: structures of O-antigen chains from the serostrain and two bacterial isolates from patients with the Guillain–Barre syndrome. Biochemistry 33: 250255.
  • Aspinall GO, McDonald AG, Pang H, Kurjanczyk LA & Penner JL (1994c) Lipopolysaccharides of Campylobacter jejuni serotype O:19: structures of core oligosaccharide regions from the serostrain and two bacterial isolates from patients with the Guillain–Barre syndrome. Biochemistry 33: 241249.
  • Bacon DJ, Szymanski CM, Burr DH, Silver RP, Alm RA & Guerry P (2001) A phase-variable capsule is involved in virulence of Campylobacter jejuni 81-176. Mol Microbiol 40: 769777.
  • Bersudsky M, Rosenberg P, Rudensky B & Wirguin I (2000) Lipopolysaccharides of a Campylobacter coli isolate from a patient with Guillain–Barre syndrome display ganglioside mimicry. Neuromuscul Disord 10: 182186.
  • Bowes T, Wagner ER, Boffey J, Nicholl D, Cochrane L, Benboubetra M, Conner J, Furukawa K & Willison HJ (2002) Tolerance to self gangliosides is the major factor restricting the antibody response to lipopolysaccharide core oligosaccharides in Campylobacter jejuni strains associated with Guillain–Barre syndrome. Infect Immunol 70: 50085018.
  • Buzby JC, Allos BM & Roberts T (1997) The economic burden of Campylobacter-associated Guillain–Barre syndrome. J Infect Dis 176 (Suppl 2), S192S197.
  • Endtz HP, Ang CW, Van Den Braak N et al. (2000) Molecular characterization of Campylobacter jejuni from patients with Guillain–Barre and Miller Fisher syndromes. J Clin Microbiol 38: 22972301.
  • Endtz HP, Van West H, Godschalk PCR et al. (2003) Risk factors associated with Campylobacter jejuni infections in Curacao Netherlands Antilles. J Clin Microbiol 41: 55935597.
  • Friedman CR, Neimann J, Wagener HC & Tauxe RV (2000) Epidemiology of Campylobacter jejuni infections in the United States and other industrialized countries. Campylobacter, 2nd edn (NachamkinI & BlaserMJ, eds), pp. 121138. ASM Press, Washington DC.
  • Fry BN, Feng S, Chen YY, Newell DG, Coloe PJ & Korolik V (2000) The galE gene of Campylobacter jejuni is involved in lipopolysaccharide synthesis and virulence. Infect Immunol 68: 25942601.
  • Goddard EA, Lastovica AJ & Argent AC (1997) Campylobacter 0:41 isolation in Guillain–Barre syndrome. Arch Dis Child 76: 526528.
  • Godschalk PC, Heikema AP, Gilbert M, Komagamine T, Ang CW, Glerum J, Brochu D, Li J, Yuki N, Jacobs BC, Van Belkum A & Endtz HP (2004) The crucial role of Campylobacter jejuni genes in anti-ganglioside antibody induction in Guillain–Barre syndrome. J Clin Invest 114: 16591665.
  • Goodyear CS, O'Hanlon GM, Plomp JJ et al. (1999) Monoclonal antibodies raised against Guillain–Barre syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations. J Clin Invest 104: 697708.
  • Gronow S, Brabetz W & Brade H (2000) Comparative functional characterization in vitro of heptosyltransferase I (WaaC) and II (WaaF) from Escherichia coli. Eur J Biochem 267: 66026611.
  • Hanahan D (1983) Studies on transformation of Escherichia coli with plasmids. J Mol Biol 166: 557580.
  • Ho TW, McKhann GM & Griffin JW (1998) Human autoimmune neuropathies. Annu Rev Neurosci 21: 187226.
  • Ho TW, Willison HJ, Nachamkin I et al. (1999) Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain–Barre Syndrome. Ann Neurol 45: 168173.
  • Hughes RA & Rees JH (1997) Clinical and epidemiologic features of Guillain–Barre syndrome. J Infect Dis 176 (Suppl 2), S92S98.
  • Kanipes MI, Holder LC, Corcoran AT, Moran AP & Guerry P (2004) A deep-rough mutant of Campylobacter jejuni 81-176 is noninvasive for intestinal epithelial cells. Infect Immunol 72: 24522455.
  • Karlyshev AV & Wren BW (2001) Detection and initial characterization of novel capsular polysaccharide among diverse Campylobacter jejuni strains using alcian blue dye. J Clin Microbiol 39: 279284.
  • Klena JD, Gray SA & Konkel ME (1998) Cloning sequencing and characterization of the lipopolysaccharide biosynthetic enzyme heptosyltransferase I gene (waaC) from Campylobacter jejuni and Campylobacter coli. Gene 222: 177185.
  • Kuroki S, Haruta T, Yoshioka M, Kobayashi Y, Nukina M & Nakanishi H (1991) Guillain–Barre syndrome associated with Campylobacter infection. Pediatr Infect Dis J 10: 149151.
  • Kusunoki S, Iwamori M, Chiba A, Hitoshi S, Arita M & Kanazawa I (1996) GM1b is a new member of antigen for serum antibody in Guillain–Barre syndrome. Neurology 47: 237242.
  • Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680685.
  • Lastovica AJ, Goddard EA & Argent AC (1997) Guillain–Barre syndrome in South Africa associated with Campylobacter jejuni O:41 strains. J Infect Dis 176 (Suppl 2), S139S143.
  • Linton D, Karlyshev AV, Hitchen PG, Morris HR, Dell A, Gregson NA & Wren BW (2000) Multiple N-acetyl neuraminic acid synthetase (neuB) genes in Campylobacter jejuni: identification and characterization of the gene involved in sialylation of lipo-oligosaccharide. Mol Microbiol 35: 11201134.
  • Lugtenberg B, Meijers J, Peters R, Van Der Hoek P & Van Alphen L (1975) Electrophoretic resolution of the “major outer membrane protein” of Escherichia coli K12 into four bands. FEBS Lett 58: 254258.
  • Magira EE, Papaioakim M, Nachamkin I, Asbury AK, Li CY, Ho TW, Griffin JW, McKhann GM & Monos DS (2003) Differential distribution of HLA-DQ beta/DR beta epitopes in the two forms of Guillain–Barre syndrome acute motor axonal neuropathy and acute inflammatory demyelinating polyneuropathy (AIDP): identification of DQ beta epitopes associated with susceptibility to and protection from AIDP. J Immunol 170: 30743080.
  • Moran AP & O'Malley DT (1995) Potential role of lipopolysaccharides of Campylobacter jejuni in the development of Guillain–Barré syndrome. J Endotoxin Res 2: 233235.
  • Nachamkin I (2002) Chronic effects of Campylobacter infection. Microbes Infect 4: 399403.
  • Nachamkin I, Allos BM & Ho T (1998) Campylobacter species and Guillain–Barre syndrome. Clin Microbiol Rev 11: 555567.
  • Nachamkin I, Engberg J, Gutacker M et al. (2001) Molecular population genetic analysis of Campylobacter jejuni HS: 9 associated with Guillain–Barre syndrome and gastroenteritis. J Infect Dis 184: 221226.
  • Nachamkin I, Liu J, Li M, Ung H, Moran AP, Prendergast MM & Sheikh K (2002) Campylobacter jejuni from patients with Guillain–Barre syndrome preferentially expresses a GD(1a)-like epitope. Infect Immunol 70: 52995303.
  • Nishimura M, Nukina M, Kuroki S, Obayashi H, Ohta M, Ma JJ, Saida T & Uchiyama T (1997) Characterization of Campylobacter jejuni isolates from patients with Guillain–Barre syndrome. J Neurol Sci 153: 9199.
  • Oldfield NJ, Moran AP, Millar LA, Prendergast MM & Ketley JM (2002) Characterization of the Campylobacter jejuni heptosyltransferase II gene waaF provides genetic evidence that extracellular polysaccharide is lipid A core independent. J Bacteriol 184: 21002107.
  • Palmer SR, Gully PR, White JM, Pearson AD, Suckling WG, Jones DM, Rawes JC & Penner JL (1983) Water-borne outbreak of Campylobacter gastroenteritis. Lancet 1: 287290.
  • Parkhill J, Wren BW, Mungall K et al. (2000) The genome sequence of the food-borne pathogen Campylobacter jejuni reveals hypervariable sequences. Nature 403: 665668.
  • Prendergast MM, Lastovica AJ & Moran AP (1998) Lipopolysaccharides from Campylobacter jejuni O:41 strains associated with Guillain–Barre syndrome exhibit mimicry of GM1 ganglioside. Infect Immunol 66: 36493655.
  • Schnaar RL, Fromholt SE, Gong Y et al. (2002) Immunoglobulin G-class mouse monoclonal antibodies to major brain gangliosides. Anal Biochem 302: 276284.
  • Sheikh KA, Nachamkin I, Ho TW et al. (1998) Campylobacter jejuni lipopolysaccharides in Guillain–Barre syndrome: molecular mimicry and host susceptibility. Neurology 51: 371378.
  • Short JM, Fernandez JM, Sorge JA & Huse WD (1988) Lambda ZAP: a bacteriophage lambda expression vector with in vivo excision properties. Nucleic Acids Res 16: 75837600.
  • Sirisena DM, MacLachlan PR, Liu SL, Hessel A & Sanderson KE (1994) Molecular analysis of the rfaD gene for heptose synthesis and the rfaF gene for heptose transfer in lipopolysaccharide synthesis in Salmonella typhimurium. J Bacteriol 176: 23792385.
  • Skirrow MB & Blaser MJ (2000) Clinical aspects of Campylobacter infection. Campylobacter, 2nd edn (NachamkinI & BlaserMJ, eds), pp. 6988. ASM Press, Washington DC.
  • Taylor DN (1992) Campylobacter jejuni infections in developing countries:current status and future trends. Campylobacter (NachamkinI, BlaserMJ & TompkinsLS, eds), pp. 2030. ASM Press, Washington DC.
  • Tsai CM & Frasch CE (1982) A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels. Anal Biochem 119: 115119.
  • Wassenaar TM, Bleumink-Pluym NM & Van Der Zeijst BA (1991) Inactivation of Campylobacter jejuni flagellin genes by homologous recombination demonstrates that flaA but not flaB is required for invasion. Embo J 10: 20552061.
  • Wassenaar TM, Fry BN & Van Der Zeijst BA (1993) Genetic manipulation of Campylobacter: evaluation of natural transformation and electro-transformation. Gene 132: 131135.
  • Wassenaar TM, Fry BN, Lastovica AJ, Wagenaar JA, Coloe PJ & Duim B (2000) Genetic characterization of Campylobacter jejuni O:41 isolates in relation with Guillain–Barre syndrome. J Clin Microbiol 38: 874876.
  • Wirguin I, Briani C, Suturkova-Milosevic L, Fisher T, Della-Latta P, Chalif P & Latov N (1997) Induction of anti-GM1 ganglioside antibodies by Campylobacter jejuni lipopolysaccharides. J Neuroimmunol 78: 138142.
  • Yuki N (2001) Infectious origins of and molecular mimicry in Guillain–Barre and Fisher syndromes. Lancet Infect Dis 1: 2937.
  • Yuki N, Sato S, Fujimoto S, Yamada S, Tsujino Y, Kinoshita A & Itoh I (1992) Serotype of Campylobacter jejuni HLA and the Guillain–Barre syndrome [letter]. Muscle Nerve 15: 968969.
  • Yuki N, Taki T, Inagaki F, Kasama T, Takahashi M, Saito K, Handa S & Miyatake T (1993) A bacterium lipopolysaccharide that elicits Guillain–Barre syndrome has a GM1 ganglioside-like structure. J Exp Med 178: 17711775.
  • Yuki N, Handa S, Tai T, Takahashi M, Saito K, Tsujino Y & Taki T (1995) Ganglioside-like epitopes of lipopolysaccharides from Campylobacter jejuni (PEN 19) in three isolates from patients with Guillain–Barre syndrome. J Neurol Sci 130: 112116.
  • Yuki N, Taki T & Handa S (1996) Antibody to GalNAc-GD1a and GalNAc-GM1b in Guillain–Barre syndrome subsequent to Campylobacter jejuni enteritis. J Neuroimmunol 71: 155161.